PTGX
Protagonist Therapeutics, IncCompany with tickers: PTGX
CIK
1377121
CUSIP
74366E102
Shares Outstanding
64,311,373
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $47,631,000 | USD | 2025-03-31 | 10-Q | 2026-05-05 |
| Research & Development | $35,893,000 | USD | 2025-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $-19,310,000 | USD | 2025-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-11,655,000 | USD | 2025-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $0.06 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-0.19 | USD/shares | 2025-03-31 | 10-Q | 2026-05-05 |